Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 275Carcinoma, Intraductal, Noninfiltrating 25Breast Carcinoma In Situ 21Neoplasm Metastasis 14Neoplasms 13Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Prostatic Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Recurrence 3Obesity 3Hot Flashes 3Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sleep Wake Disorders 2Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Tamoxifen × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡